Biorevolution UCITS ETF (WDNA)
XMIL 
BATS Primary XMIL Summary
WDNA Chart
Opportunities in Biotechnology Will Follow Advancements in the Science
By Christopher Gannatti, CFA Key Takeaways Recent advancements in GLP-1 drugs, such as Ozempic and Wegovy, underscore their potential to transform health care by addressing obesity, cardiovascular diseases and even neurodegenerative conditions.
Biorevolution UCITS ETF (WDNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biorevolution UCITS ETF ever had a stock split?
Biorevolution UCITS ETF Profile
| XMIL Exchange | US Country |
Overview
The described fund is an investment vehicle that aims to match the performance of a specific index, which is focused on global companies expected to benefit from advancements in genetics and biotechnology. To achieve its investment objective, the fund employs a representative sampling strategy. This involves investing in a subset of securities from the index that are thought to have similar risk, return, and other characteristics as the entire index. This approach allows the fund to approximate the performance of the entire index without needing to invest in all the securities it comprises. The index itself zeroes in on exchange-listed companies worldwide poised for significant growth due to breakthroughs in genetics and biotechnology. It is important to note that this fund is non-diversified, meaning it may invest more heavily in fewer securities, possibly increasing its risk relative to diversified funds.
Products and Services
The fund offers investment products and services focused on the biotechnology and genetics sectors. These can be predominantly categorized into:
- Representative Sampling Strategy Investment
This service involves the fund investing in a sample of securities from its targeted index. These securities are selected based on their similarity in risk, return, and other characteristics to the index as a whole. The objective is to closely replicate the index's performance through this sample rather than mirroring every security in the index. This strategy is employed to manage costs and ensure efficient tracking of the index's performance.
- Exposure to Global Biotechnology and Genetics Companies
The primary product of the fund is its provision of exposure to a portfolio of equity securities. These securities are from companies expected to experience significant transformation due to advancements in the fields of genetics and biotechnology. The global scope of the index ensures that investors have exposure to leading companies in these sectors from around the world, allowing for growth opportunities beyond domestic markets. The fund targets companies that are at the forefront of innovation in these fields, potentially offering higher growth prospects compared to broader market investments.
